Group MDMA-therapy for Veterans With PTSD

Summary

This Phase 2a, open-label, non-randomized, 3-cohort study assesses the feasibility and safety of MDMA-assisted group therapy for the treatment of PTSD in veterans. The study will be conducted in up to N=18 participants, recruited in three cohorts of six participants each and receive therapy sessions throughout their participation in these group cohorts.

Timeline

Start

2023-10-01

Primary completion

2025-03-14

Completion

2025-03-14

Publications

• Kachmarik JE, Loftis JM, Stauffer CS. Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study. Front Neurosci. 2026 Mar 23;20:1716817. doi: 10.3389/fnins.2026.1716817. eCollection 2026.

Drugs

Indications